Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Lange, M. Arzt, M. Pfeifer (Regensburg, Donaustauf, Germany). Switch from sitaxentan to another ERA in PAH: Single center short term safety observations. Eur Respir J 2011; 38: Suppl. 55, 2283

Member's Comments

No comment yet.

Related content which might interest you: Switching from PDE5i to riociguat in patients with PAH: A responder analysis from REPLACE Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Functional effects of long term ICS treatment in controlled asthma Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Efficacy and safety of pirfenidone in patients with IPF. A single center real-life experience. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Long term outcome of PAH therapy - the past and the future Source: Annual Congress 2008 - Current and future pulmonary arterial hypertension combination therapy Year: 2008 Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study Source: Virtual Congress 2020 – ALERT: Pneumothorax, cough, PAH, alveolar proteinosis Year: 2020 Late Breaking Abstract - Influence of salbutamol use on symptomatic outcomes with maintenance bronchodilators: a pre-specified analysis of the EMAX trial Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Efficacy of CPAP and NIV in long term treatment of OHS: the results of the Spanish multicentre randomised trial "Pickwicks" Source: International Congress 2015 – Sleep-disordered breathing Year: 2015 Late Breaking Abstract - Long-term safety of pirfenidone in a real-world setting: final results from the prospective, observational PASSPORT registry Source: International Congress 2017 – Late-breaking findings in pulmonary diseases Year: 2017 Understanding the potential long-term impacts on function with Tiotropium: the UPLIFT trial - Design and efficacy data Source: Annual Congress 2008 - Clinical trial - Understanding the potential long-term impacts on function with Tiotropium: the UPLIFT trial Year: 2008 Understanding the potential long-term impacts on function with Tiotropium: the UPLIFT trial - Safety data Source: Annual Congress 2008 - Clinical trial - Understanding the potential long-term impacts on function with Tiotropium: the UPLIFT trial Year: 2008 The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Feasibility of digital long term follow up after pulmonary rehabilitation in patients with COPD: a pilot study Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation Year: 2020 Long-term safety data with once-daily budesonide in mild asthma: results from the START study Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003 Long term outcomes of immunomodulatory drugs in SSc-ILD - data from the German SSc-network Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Consistent benefit across multiple exacerbation endpoints Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Safety and tolerability to long term moxifloxacin treatment in 38 patients with difficult to manage tuberculosis: preliminary data Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004 Clinical benefits and safety of long term treatment with montelukast (M) in patients with mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001